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Background: Hypereosinophilic syndromes (HES) are a heterogeneous group of conditions that
are characterized by tissue-associated eosinophilic inflammation and peripheral eosinophilia.
Although clinical and radiologic features associated with most forms of eosinophilic lung
diseases are relatively well-described, there is little known regarding lung involvement in
HES. The aims of the present study were to ascertain the frequency of pulmonary involvement
in HES and define associated clinical and radiologic features.
Methods: We included all patients with HES seen over a 5-year period from 2004 to 2008 and
examined their medical records and radiologic studies to obtain relevant data.
Results: There were 49 patients (25 males and 24 females) with a median age of 50 years
(range, 12e88 years); 18 (37%) had a history of tobacco use. In 12 patients (24%), these pulmo-
nary manifestations were attributable to parenchymal lung involvement with HES. Radiologic
manifestations of pulmonary involvement varied but most commonly consisted of patchy
ground-glass opacities and consolidation; one patient exhibited numerous pulmonary nodules.
Thirteen patients (27%) had asthma including 6 with a new diagnosis of this disorder. Initial
treatment usually consisted of corticosteroids but additional therapeutic agents were em-
ployed during the clinical course and included hydroxyurea, interferon-a, imatinib, and mepo-
lizumab. Most patients with pulmonary involvement with HES improved and no deaths were
observed.
Conclusion: One-quarter of HES patients manifested pulmonary involvement with variable
radiologic findings. Asthma was more common in HES than previously reported. Most patients
with pulmonary involvement in HES improve with currently available therapies.
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Lung in hypereosinophilic syndromes 115Introduction
Mayo Foundation Institutional Review Board prior toHypereosinophilic syndromes (HES) are a heterogeneous
group of conditions that are characterized by tissue-asso-
ciated eosinophilic inflammation and peripheral eosino-
philia.1,2 The term, hypereosinophilic syndromes, was first
coined in 1968 by Hardy and Anderson in describing three
patients with diverse clinical presentations.3 In 1975,
Chusid and colleagues4 proposed 3 criteria for diagnosing
HES: (1) a persistent eosinophilia of 1.5  109/L for longer
than 6 months, (2) a lack of evidence for parasitic, allergic
or other known causes of eosinophilia, and (3) signs and
symptoms of eosinophil-mediated organ dysfunction. More
recently, Roufosse and colleagues5 proposed that minimum
duration (6 months) of eosinophilia criterion need not
necessarily be fulfilled since some patients may require
prompt treatment to mitigate end-organ damage. In addi-
tion, discovery of the myeloproliferative and T-cell
lymphocytic variants of HES has led to classifying subtypes
of hypereosinophilic syndromes.2,5
A spectrum of eosinophilic lung diseases is currently
recognized and includes acute eosinophilic pneumonia,
Lo¨ffler’s syndrome (simple pulmonary eosinophilia), chronic
eosinophilic pneumonia, ChurgeStrauss syndrome, eosino-
philic bronchitis, allergic bronchopulmonary aspergillosis,
drug-induced eosinophilic lung disease, parasitic infections,
and HES.6e8 Although clinical and radiologic features asso-
ciated with most of these eosinophilic lung diseases are
relatively well-described, there is little known regarding
lung involvement in HES, partly due to the rarity of this
disorder.
In this study, we sought to ascertain the frequency of
lung involvement in patients with HES and define associated
clinical and radiologic features including the clinical course
of these patients.Methods
The study was undertaken at Mayo Clinic in Rochester,
Minnesota, USA. A computer-assisted search was per-
formed to identify all cases of HES diagnosed during a 5-
year period from January 1, 2004 to December 31, 2008.
HES was defined by the following criteria: (1) evidence of
chronic illness lasting more than 6 months with blood
eosinophilia of greater than 1500/ml (>1.5  109/L)
present on at least 2 occasions; (2) absence of other
identifiable etiologies for eosinophilia including drugs,
parasitic infection, malignancies, and allergic disease; (3)
presence of signs and symptoms of organ dysfunction; (4)
absence of recognized specific disease entities including
ChurgeStrauss vasculitis, acute or chronic eosinophilic
pneumonia, allergic bronchopulmonary aspergillosis, and
eosinophilic fasciitis.1,4,5,8 Specifically, none of the
patients exhibited anti-neutrophil cytoplasmic antibodies,
histologic evidence of vasculitis, IgE or IgG antibody to
Aspergillus fumigatus, or radiologic features of central
bronchiectasis.
Medical records were reviewed and a total of 49 patients
with HES were identified. Approval was obtained from thebeginning the study.
Data collection and analysis
Medical records of all patients confirmed as having HES
were reviewed to extract data regarding demographics,
clinical presentation, imaging and laboratory studies,
comorbidities, diagnostic testing, treatment, and clinical
course. In those patients with pulmonary manifestations,
clinical or radiologic, determination was made as to
whether the manifestation was directly related to pulmo-
nary involvement with HES or not. Those patients desig-
nated as having pulmonary involvement with HES were
required to have intrathoracic abnormality demonstrated
on chest radiography or CT, no other plausible explanation
for the intrathoracic finding, e.g., cardiac disease or
infection, and one of the following: 1) evidence of eosin-
ophilia on lung biopsy, bronchoalveolar lavage fluid, pleural
fluid, or sputum, or 2) improvement of intrathoracic disease
with treatment of HES.
Follow-upperiodwasdefinedas the interval fromthe time
of HES diagnosis to the date of the last available medical
evaluation documented in the medical records.Results
Demographic and clinical features
The study included49patients, including 25men (51%) and24
women (49%), with median age of 50 years (range, 12e88
years). Eighteen (37%) were previous or current tobacco
users. The median duration of illness at presentation was 9
months (range, 1 month to 17 years). Four patients (8%) had
myeloproliferative variant of HES with evidence of fusion of
the Fip1-like 1 gene to the platelet-derived growth factor
receptor a gene (FIP1L1-PDRGFRa) in 2 patients (all 49
patients were tested for FIP1L1-PDRGFRa fusion gene) and
chronic eosinophilic leukemia in 2 other patients. Four
patients (8%) were identified to have lymphocytic variant of
HES with monoclonal T-cells (41 patients underwent
lymphocyte phenotyping and 33 patients were tested for
clonal T-cell receptor gene rearrangement). There were no
patients with familial HES. The remaining 41 patients (84%)
were diagnosed as idiopathic HES.
Thirty-one patients (63%) had one or more respiratory
symptom including dyspnea (45%), cough (39%), and
wheezing (24%) at initial presentation. Five patients (10%)
manifested inspiratory crackles on auscultation of the lung.
Skin rash had occurred in 19 patients (39%). Constitutional
symptoms including fatigue, malaise, fever, night sweats,
anorexia, weight loss, and/or myalgias were present in 27
patients (55%).
Chest radiography or CT revealed abnormal findings in 21
patients (43%) and included parenchymal infiltrates (37%),
pleural effusion (14%), intrathoracic lymphadenopathy
(12%), and pulmonary emboli (4%). The intrathoracic
lymphadenopathy consisted of mildly enlarged mediastinal
nodes with the exception of one patient who also had
mildly enlarged hilar lymph nodes bilaterally. The pleural
Table 1 Demographic, clinical, and radiologic features of 12 patients with pulmonary involvement in HES.
Case
no.
Age,
year/sex
Presenting
symptoms
Type of HES CT findings Pulmonary
function
Lung biopsy Treatment
1 57/M Cough,
weight loss
Idiopathic Peripheral GGOs, bilateral
pleural effusions
Mild obstruction ND Prednisone
2 88/M Dyspnea,
cough, rash
Idiopathic Patchy GGOs and
consolidation
Mild obstruction Bronchoscopic e
focal eosinophilic
infiltrate
Prednisone
3 44/M Cough,
rash, fever,
night sweats
Idiopathic Patchy GGOs and
consolidation,
mediastinal
lymphadenopathy,
bilateral pleural effusions
Mild obstruction ND Prednisone,
hydroxyurea,
imatinib
4 48/F Pruritus,
arthralgias,
weight loss,
night sweats
T-cell
lymphoproliferative
variant
Patchy GGOs, bilateral
pleural
effusions
Normal ND Prednisone,
interferon-a2b,
hydroxyurea,
imatinib
5 20/F Dyspnea,
headaches,
myalgias,
fatigue
Idiopathic Focal consolidation Normal Surgical e
eosinophilic
pneumonia,
bronchiolectasis
Prednisone,
imatinib,
mepolizumab
6 22/M Dyspnea,
chest pain,
rash,
arthralgias,
fatigue,
night sweats
Idiopathic Patchy GGOs and
consolidation,
right pleural effusion
Mild obstruction ND (Eosinophilic
pleural effusion)
Prednisone,
interferon-a2b,
hydroxyurea
7 53/F Dyspnea, cough,
wheeze,
diarrhea,
weight loss
Idiopathic Patchy GGOs and nodules Severe
obstruction,
decreased
diffusing
capacity
Bronchoscopic e
focal
eosinophilic
infiltrate
Prednisone,
hydroxyurea,
interferon-a2b
8 48/M Dyspnea, myalgias,
fever, nausea
Idiopathic Patchy GGOs and
consolidation,
mediastinal
lymphadenopathy
Moderate
obstruction,
decreased
diffusing
capacity
Bronchoscopic e
respiratory
bronchiolitis
with eosinophils
Prednisone
9 68/F Cough, dyspnea,
rash
Idiopathic Extensive GGOs and
consolidation,
left pleural effusion
ND ND (Sputum
eosinophilia)
Prednisone,
interferon-a2b
10 68/F Fatigue, dyspnea Idiopathic Peripheral GGOs Normal ND Prednisone,
interferon-a2b,
hydroxyurea
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Lung in hypereosinophilic syndromes 117effusion was small in all 7 patients with this finding and
present bilaterally in 5 of these patients.Pulmonary involvement in HES
Critical review of those patients with imaging abnormalities
suggested that the intrathoracic findings represented direct
pulmonary involvement with the eosinophilic infiltrative
process in 12 of these patients, 2 of whom did not have
respiratory symptoms or signs despite the presence of
bilateral parenchymal infiltrates. In the remaining 9
patients, alternative causes of intrathoracic findings
included cardiac disease with pulmonary congestion,
pulmonary embolism, drug-induced lung disease (amiodar-
one), infection, aspiration, and chronic nonspecific fibrosis.
Details regarding the 12 patients (24% of total) with
pulmonary involvement in HES are outlined in Table 1. Eight
of these patients were never-smokers, one ex-smoker, and
3 were current smokers. Eosinophilic infiltrates were found
in all 5 patients who underwent a lung biopsy procedure
that included 2 video-assisted thoracoscopic surgical (VATS)
biopsies and 3 bronchoscopic biopsies. One of the VATS
biopsies (case #12) showed multiple well circumscribed
nodules composed of a bland vascular proliferation
admixed with numerous eosinophils and scattered
lymphocytes (Fig. 1a and b). Eosinophils were also present
in alveolar septa and in distal airspaces away from the
nodules. These findings were most consistent with angio-
lymphoid hyperplasia (epithelioid hemangioma) of the lung.
The other VATS biopsy (case #5) was not available for
current review but reportedly showed histologic features of
eosinophilic pneumonia, characterized by collections of
eosinophils and macrophages in airspaces, and a mild
interstitial inflammatory infiltrate. The transbronchial
biopsies showed sparse and patchy infiltrates of eosinophils
in the lamina propria of airway walls (Fig. 1c) and in alve-
olar septa (Fig. 1d and e). Eosinophilia was noted on pleural
fluid examination (in the absence of prior pneumothorax or
pleural procedure) in one additional patient and in
a sputum sample in another patient (Fig. 1f). In the
remaining 5 patients, radiologic abnormalities improved
with treatment of the underlying HES, and there were no
other likely causes for the intrathoracic findings.
Radiologic manifestations of pulmonary involvement in
HES most commonly consisted of patchy ground-glass
opacities (GGOs) and consolidation (Fig. 2). In one patient
(case #9), these infiltrates were extensive and involved
nearly half of the left lung (Fig. 3). In another patient (case
#12), nodular opacities were noted diffusely throughout
both the lungs (Fig. 4).
All 12 patients with pulmonary parenchymal involvement
with HES were initially treated with corticosteroids. Other
treatments included interferon-a2b, hydroxyurea, imatinib,
and mepolizumab. The median follow-up was 14 months
(range, 2e48 months) with no known deaths. Ten of these 12
patients experienced symptomatic and radiologic improve-
ment on the treatment regimens outlined in Table 1.
The remaining 2 patients were stable (case #4, 11) and in the
process of modifying their treatment regimens.
Thirteenpatients (27%)hadasthma.Therewasahistory of
asthma in 7 additional patients but the diagnosis could not be
Figure 1 Morphologic findings in HES patients with lung involvement. a, b, VATS biopsy (case #12, Table 1) of angiolymphoid
hyperplasia with eosinophilia (epithelioid hemangioma), forming nodules in the lung (low and high power). cee, Transbronchial
biopsies (case #7, Table 1) with scattered eosinophils in the subepithelial tissue of bronchioles (c) and in alveolar septa (d, e). f,
Eosinophils in lavage specimens are recognized by their bilobed nucleus (straight arrows), compared with the polymorphonuclear
appearance of neutrophils (curved arrow).
118 M.M. Dulohery et al.confirmed due to absence of documented reversible airflow
obstruction. In 6 of 13 patients with confirmed asthma,
asthma was diagnosed at the time of their presentation with
HES and includes 2 of those described in Table 1 (case #7, 8).
One of these patients (case #7) who presented with persis-
tent dyspnea, cough, wheezing, diarrhea, abdominal pain,
and 23-kg weight loss exhibited severe airflow obstruction
(forced expiratory volume in 1 s [FEV1] 0.45 L, 16% predicted)
without acute response to inhaled bronchodilator and
a severely decreased diffusing capacity (26% predicted) on
pulmonary function testing. Prednisone treatment was
initiated at 60 mg per day with gradual tapering of the dose.
Five weeks later (on prednisone 40mg per day), her FEV1 had
improved to 1.96 L (71% predicted) and the diffusing capacity
was within normal range. Because her HES repeatedly wors-
ened with tapering of the prednisone dose, hydroxyurea wasadded to her regimen which was later replaced with inter-
feron-a2b therapy.Discussion
Hypereosinophilic syndromes are characterized by periph-
eral eosinophilia and eosinophil-mediated organ dysfunc-
tion resulting in diverse clinical manifestations. Although
lung involvement has been reported to occur in up to 63% of
patients, associated clinical and radiologic features have
not been well defined.1,5,9 In our study, 67% of the patients
had respiratory symptoms and/or radiologic abnormalities
on chest imaging. Dyspnea and cough were most common
symptoms as noted in previous studies. However, less than
one-half of these patients (24% of all patients) had
Figure 2 High-resolution CT scan of the chest of a 48-year-
old man with HES (case #8, Table 1) demonstrating predomi-
nantly peripheral opacities of consolidative and ground-glass
character in a patchy distribution.
Figure 4 High-resolution CT scan of the chest of a 32-year-
old woman (case #12, Table 1) demonstrating nodular opacities
present diffusely throughout both lungs.
Lung in hypereosinophilic syndromes 119evidence that the intrathoracic manifestations were
directly attributable to HES, i.e., eosinophilic infiltration of
the lung. Other causes for respiratory manifestations
included cardiac disease, pulmonary embolism, drugs,
infection, aspiration, asthma, and other issues.
HES has previously been reported to be more common in
men than women with a ratio of 9:1.1,5,9 In our study, we
noted a 1:1 ratio of men to women. This equal distribution
between sexes was also noted in a recent study of mepo-
lizumab therapy for HES patients who do not have the
FIP1L1-PDRGFRa fusion gene.10 Although HES related to
FIP1L1-PDRGFRa fusion gene occurs almost exclusively in
men, idiopathic HES and the lymphocytic variant of HES are
equally distributed between the sexes. Most of our patients
with HES including those with pulmonary involvement had
idiopathic HES. The median age at diagnosis of 50 years inFigure 3 High-resolution CT scan of the chest of a 68-year-
old woman (case #9, Table 1) demonstrating extensive con-
solidative and ground-glass opacities in the left lung with
minimal involvement seen in the right lung.our study cohort is similar to that reported in previous
studies.4,9,10
There was a relatively high frequency of asthma (27%) in
our cohort of HES patients. In 6 of these patients asthma
was diagnosed at the time of their presentation with HES.
All 13 patients had reversible airflow obstruction or a posi-
tive methacholine challenge test. Our findings are contrary
to those of Spry and colleagues11,12 who reported that
asthma was rare in HES patients. Our results suggest that
asthma may be a manifestation of HES in some patients
with this disorder. This association may be expected given
the prominent role of eosinophils in the pathogenesis of
asthma. In a patient with chronic asthma and persistent
peripheral eosinophilia, the diagnosis of HES needs to be
considered.
Pulmonary abnormalities on radiologic studies have been
described in 14e28% of patients with HES and have con-
sisted of nodules, ground-glass opacities, interlobular
septal thickening, and pleural effusion.13e15 In these
previous studies, however, it was unclear whether the
intrathoracic findings were directly attributable to eosino-
philic infiltration or not. In our study, radiologic features
most commonly consisted of a combination of ground-glass
opacities and consolidation in a patchy distribution. In 2 of
these patients, there was a peripheral distribution of these
opacities, similar to that associated with chronic eosino-
philic pneumonia, while in other patients the distribution
was random. In patients with chronic eosinophilic pneu-
monia and extrapulmonary manifestations, alternative
diagnosis of HES needs to be entertained. In 2 of our 12
patients, parenchymal involvement was detected by CT
scanning in the absence of respiratory symptoms. In one
patient, nodules were the predominant finding. This broad
spectrum of radiologic findings is not surprising given the
etiologic heterogeneity of HES that has been recognized
through recent molecular diagnostic techniques.
Surgical lung biopsy is seldom performed in HES because
pulmonary involvement may sometimes be inferred from
the combination of clinical context and radiologic findings
or established by bronchoalveolar lavage or transbronchial
biopsy.16 One of our patients underwent a surgical lung
biopsy (case #12) which revealed angiolymphoid
120 M.M. Dulohery et al.hyperplasia with eosinophilia (epithelioid hemangioma) of
the lung, a condition that most commonly affects the
subcutaneous tissues and rarely involves the lung.17
Recently reported association of this histologic finding
with clonal
T-cell proliferations raises the possibility that this case may
be an example of pulmonary involvement in lymphocytic
variant of HES.18 Clonality assessment was not performed
in this particular patient. Increased number of eosinophils
in the bronchoalveolar lavage fluid or eosinophilic infiltrate
observed on the lung biopsy is not diagnostically specific
but documents pulmonary involvement in patients with
HES.
The majority of patients with HES have idiopathic HES,
as noted in our study. For these patients, initial therapy is
usually corticosteroids.2,6 For those patients who do not
respond adequately or tolerate corticosteroid therapy
poorly, interferon-a, hydroxyurea, imatinib, and various
chemotherapeutic agents have been used.2,6,19 Rothenberg
and colleagues10 recently reported the use of mepolizumab
(a humanized anti-interleukin-5 antibody) in patients with
HES without the FIP1L1-PDRGFRa fusion gene and on
prednisone therapy. Mepolizumab therapy was found to be
an effective corticosteroid-sparing agent in these patients.
The myeloproliferative variants of HES (including that
associated with FIP1L1-PDRGFRa fusion gene) have been
found to be responsive to treatment with the tyrosine
kinase inhibitor, imatinib, which has become the first-line
therapy for this variant of HES.1,5 Hematopoietic stem cell
transplantation is another option, particularly for those
who are resistant to pharmacologic therapy.20
Due to its rarity, HES is a diagnosis thatmay be overlooked
in the evaluation of patients with eosinophilic lung disease.
For example, some patients with HES and pulmonary
involvement may initially be diagnosed to have chronic
eosinophilic pneumonia particularly in the absence of overt
extrapulmonary manifestations. Furthermore, the boundary
between HES and other eosinophilic lung diseases such as
ChurgeStrauss vasculitis can be blurred since these two
disorders share some clinical manifestations such as asthma
and peripheral neuropathy. Thus, judicious use of serologic
studies, molecular testing for FIP1L1-PDRGFRa mutation,
T-lymphocyte immunophenotyping, bone marrow examina-
tion, CT scanning of the chest, and tissue biopsy is needed
along with appropriate clinical correlation to distinguish
various forms of eosinophilic lung disease.
Limitations of this study are related to its retrospective
nature and modest number of patients with this rare
disorder. Clinical data were limited to those documented in
the medical records. The diagnostic evaluation and treat-
ment regimens employed were determined by individual
physicians, usually hematologists and allergy/immunology
specialists, involved in the care of these patients. Similarly,
follow-up information, including subsequent radiologic
studies, was limited to those contained in the medical
records.
Nonetheless, our study provides new insights into the
frequency and spectrum of pulmonary involvement in HES
as well as the clinical course associated with this process.
Although respiratory symptoms are relatively common in
patients with HES, they may not necessarily be due to
eosinophilic infiltration of the lung. CT scanning,bronchoscopy and, sometimes, surgical lung biopsy may
be needed to clarify the cause of pulmonary manifesta-
tions in patients HES. Aside from parenchymal involve-
ment, our data suggest that asthma may be a component
of HES in some patients. Most patients with pulmonary
involvement in HES respond favorably to currently avail-
able therapies.
Conclusion
One-quarter of HES patients manifested pulmonary
involvement with variable radiologic findings but most
commonly consist of patchy GGOs and consolidation.
Asthma was more common in HES than previously reported.
Most HES patients with pulmonary involvement experience
improvement with currently available therapies.
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